Canopy Growth（WEED）株式概要
キャノピー・グロース・コーポレーションは、その子会社とともに、主に米国、カナダ、ドイツ、および国際的なレクリエーションおよび医療目的の大麻および大麻ベースの製品の生産、流通、販売に従事している。 詳細
WEED Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Canopy Growth Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | CA$1.51 |
| 52週高値 | CA$3.28 |
| 52週安値 | CA$1.18 |
| ベータ | 2.39 |
| 1ヶ月の変化 | -6.21% |
| 3ヶ月変化 | -6.21% |
| 1年変化 | -40.55% |
| 3年間の変化 | -87.72% |
| 5年間の変化 | -99.50% |
| IPOからの変化 | -94.17% |
最新ニュース
ナラティブの更新 • May 13
WEED: Expanded Product Line And Equity Raise Will Drive Future Upside
Analysts have modestly reduced their price target on Canopy Growth to CA$2.38, citing slightly higher assumed discount rates, a somewhat stronger profit margin outlook, and a lower future P/E multiple in their refreshed models. What's in the News Canopy Growth and its medical brand Spectrum Therapeutics expanded their Minor Cannabinoid softgel lineup, adding new 30 and 90 pack formats and more dosing options across the Optimized Spectrum portfolio for both daytime and nighttime use (Key Developments).
ナラティブの更新 • Apr 26
WEED: New Brand Launch And Equity Raise Will Support Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from CA$5.00 to CA$4.82, citing updated assumptions that include a slightly lower revenue growth outlook, a higher profit margin and a reduced future P/E multiple. What's in the News Canopy Growth launched Deelish, a new cannabis brand aimed at everyday consumers, with products positioned at everyday price points and high THC content across both flower and pre-roll formats (Key Developments).ナラティブの更新 • Apr 11
WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside
Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.Recent updates
ナラティブの更新 • May 13
WEED: Expanded Product Line And Equity Raise Will Drive Future Upside
Analysts have modestly reduced their price target on Canopy Growth to CA$2.38, citing slightly higher assumed discount rates, a somewhat stronger profit margin outlook, and a lower future P/E multiple in their refreshed models. What's in the News Canopy Growth and its medical brand Spectrum Therapeutics expanded their Minor Cannabinoid softgel lineup, adding new 30 and 90 pack formats and more dosing options across the Optimized Spectrum portfolio for both daytime and nighttime use (Key Developments).ナラティブの更新 • Apr 26
WEED: New Brand Launch And Equity Raise Will Support Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from CA$5.00 to CA$4.82, citing updated assumptions that include a slightly lower revenue growth outlook, a higher profit margin and a reduced future P/E multiple. What's in the News Canopy Growth launched Deelish, a new cannabis brand aimed at everyday consumers, with products positioned at everyday price points and high THC content across both flower and pre-roll formats (Key Developments).ナラティブの更新 • Apr 11
WEED: Everyday Brand Launch And Equity Raise Will Support Future Upside
Analysts have adjusted their CA$ price target on Canopy Growth to reflect updated views on long term revenue growth, profit margin assumptions, and a lower projected future P/E multiple. This has resulted in a slightly different outlook than before.ナラティブの更新 • Mar 28
WEED: Term Loan Refinancing Will Support Medical Expansion And New Formats
Analysts have reduced their Canopy Growth fair value estimate from CA$3.20 to about CA$2.38, citing updated assumptions around revenue growth, profit margins, the discount rate, and a lower expected future P/E multiple. What's in the News Canopy Growth filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at $1.03 each (Key Developments).ナラティブの更新 • Mar 13
WEED: Term Loan And Equity Raise Will Support Future Acquisitions
Analysts have trimmed their CA$ price target on Canopy Growth, citing slightly higher projected revenue growth, a lower profit margin outlook, and a higher assumed future P/E multiple. Together, these factors imply a more cautious stance on the shares.ナラティブの更新 • Feb 26
WEED: Term Loan And Equity Raise Will Support Future Portfolio Expansion
Analysts have adjusted their price target on Canopy Growth to CA$5.00, reflecting updated assumptions for revenue growth, profit margins, and a slightly lower future P/E multiple. What's in the News Filed a follow-on equity offering of approximately $19.27 million, covering 18,705,578 common shares priced at about $1.03 per share (Key Developments).ナラティブの更新 • Feb 11
WEED: Term Loan Funding Will Support Expansion Of Medical And Adult-Use Portfolio
Analysts have trimmed their fair value estimate for Canopy Growth from $8.00 to $5.00, citing higher assumed revenue growth of 14.73% paired with much thinner profit margins of 4.78% and a very large 137.82x future P/E, which together point to a riskier and more expensive earnings profile. What's in the News Canopy Growth entered a term loan agreement to receive net proceeds of US$150 million from lenders led by JGB Management Inc., with the loan maturing in January 2031.ナラティブの更新 • Jan 27
WEED: Medical Expansion And New Product Formats Will Drive Future Upside
Analysts have trimmed their fair value estimate for Canopy Growth from US$3.76 to about US$3.20. This reflects updated assumptions around slower revenue growth, a slightly lower future P/E, and a broadly unchanged margin and discount rate profile.分析記事 • Jan 11
More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 28%
Canopy Growth Corporation ( TSE:WEED ) shares have had a horrible month, losing 28% after a relatively good period...ナラティブの更新 • Jan 11
WEED: Medical And Adult Use Product Expansion Will Drive Future Upside
Analysts have made only very small tweaks to their inputs for Canopy Growth, keeping the fair value estimate steady at $3.76 while slightly adjusting assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these changes support a largely unchanged price target outlook.ナラティブの更新 • Dec 23
WEED: Medical Expansion Will Drive Future Upside For Shares
Analysts have nudged their price target on Canopy Growth higher to reflect an improved fair value estimate, rising from approximately $3.30 to $3.76. This revision is supported by slightly stronger projected revenue growth, a notable uplift in expected profit margins, and a lower anticipated future price to earnings multiple.ナラティブの更新 • Dec 08
WEED: Medical Expansion And Share Consolidation Will Drive Future Upside
Analysts have modestly adjusted their price target on Canopy Growth, citing largely unchanged assumptions for fair value at approximately 3.30 dollars, a stable discount rate near 6.12 percent, and essentially flat outlooks for revenue growth, profit margins, and future valuation multiples. What's in the News Launched Claybourne Gassers All in One vapes featuring high potency liquid diamonds and anti clog, anti burn technology, along with new Claybourne Frosted Flyers infused pre roll variety packs in select Canadian regions and online medical channels (Key Developments) Expanded the Spectrum Therapeutics portfolio in Australia with new CBD, THC, and balanced softgel capsules, deepening the company’s presence in the maturing Australian medical cannabis market (Key Developments) Shareholders approved amendments to the company’s articles to allow a potential consolidation of common and exchangeable shares, giving the board discretionary authority to implement a reverse split within 12 months (Key Developments) Transitioned the DOJA facility in Kelowna, British Columbia, into an exclusive medical cultivation site under a micro cultivation license, focused on small batch craft cannabis for Spectrum Therapeutics patients, including veterans (Key Developments) Appointed Tom Stewart as permanent Chief Financial Officer, formalizing his role after serving as interim CFO and leading efforts to stabilize the balance sheet, cut expenses, and improve liquidity (Key Developments) Valuation Changes Fair Value: Unchanged at approximately CA$3.30 per share, indicating no material revision to intrinsic value estimates.ナラティブの更新 • Nov 24
WEED: Improving Profit Margins And Share Consolidation Will Drive Future Upside
Analysts have raised their price target for Canopy Growth from $1.30 to $3.30. They cite improvements in profit margin projections and expectations of sustained profitability, despite moderated revenue growth forecasts.分析記事 • Nov 15
Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Canopy Growth Corporation ( TSE:WEED ) shares have had a horrible month, losing 26% after a relatively good period...分析記事 • Nov 10
Canopy Growth Corporation (TSE:WEED) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Last week, you might have seen that Canopy Growth Corporation ( TSE:WEED ) released its second-quarter result to the...ナラティブの更新 • Nov 10
WEED: Rising Discount Rate Will Pressure Share Price In The Months Ahead
Analysts have adjusted their price target for Canopy Growth downward from $2.64 to $1.30. They cited an increased discount rate as well as ongoing evaluations of profit margin and future earnings potential.分析記事 • Aug 30
Revenues Tell The Story For Canopy Growth Corporation (TSE:WEED) As Its Stock Soars 70%
Canopy Growth Corporation ( TSE:WEED ) shares have had a really impressive month, gaining 70% after a shaky period...ナラティブの更新 • Aug 07
European Expansion And Operational Improvements Will Unlock Cannabis Potential
Consensus analyst price targets for Canopy Growth have been revised lower primarily due to a marked slowdown in forecast revenue growth, resulting in a fair value decrease from CA$3.31 to CA$2.98. What's in the News Canopy Growth introduced its Canadian-grown 7ACRES brand in Australia, expanding its medical cannabis portfolio with high-THC sativa strains Ultra Jack and Jack Frost.分析記事 • May 18
Investors Appear Satisfied With Canopy Growth Corporation's (TSE:WEED) Prospects As Shares Rocket 40%
Those holding Canopy Growth Corporation ( TSE:WEED ) shares would be relieved that the share price has rebounded 40% in...分析記事 • Apr 02
What You Can Learn From Canopy Growth Corporation's (TSE:WEED) P/S After Its 28% Share Price Crash
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 28% in the last...
新しいナラティブ • Mar 31
New Medical Cannabis And Vaporizer Offerings Will Expand Global Markets
Growth in the medical cannabis sector and product innovation in adult-use and premium vaporizers position Canopy for revenue and market share expansion.分析記事 • Feb 12
Canopy Growth Corporation's (TSE:WEED) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 26% in the last...分析記事 • Dec 22
Canopy Growth Corporation's (TSE:WEED) Popularity With Investors Under Threat As Stock Sinks 26%
Unfortunately for some shareholders, the Canopy Growth Corporation ( TSE:WEED ) share price has dived 26% in the last...分析記事 • Nov 05
Canopy Growth Corporation (TSE:WEED) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Canopy Growth Corporation ( TSE:WEED ) shareholders are no doubt pleased to see that the share price has bounced 28% in...分析記事 • Aug 28
More Unpleasant Surprises Could Be In Store For Canopy Growth Corporation's (TSE:WEED) Shares After Tumbling 26%
To the annoyance of some shareholders, Canopy Growth Corporation ( TSE:WEED ) shares are down a considerable 26% in the...分析記事 • Aug 17
We Think Canopy Growth (TSE:WEED) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jun 15
Some Confidence Is Lacking In Canopy Growth Corporation (TSE:WEED) As Shares Slide 26%
Canopy Growth Corporation ( TSE:WEED ) shares have retraced a considerable 26% in the last month, reversing a fair...株主還元
| WEED | CA Pharmaceuticals | CA 市場 | |
|---|---|---|---|
| 7D | 6.3% | 3.0% | 2.5% |
| 1Y | -40.6% | 46.0% | 33.9% |
業界別リターン: WEED過去 1 年間で46 % の収益を上げたCanadian Pharmaceuticals業界を下回りました。
リターン対市場: WEEDは、過去 1 年間で33.9 % のリターンを上げたCanadian市場を下回りました。
価格変動
| WEED volatility | |
|---|---|
| WEED Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 11.6% |
| Market Average Movement | 10.2% |
| 10% most volatile stocks in CA Market | 17.7% |
| 10% least volatile stocks in CA Market | 3.9% |
安定した株価: WEED 、 Canadian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: WEEDの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| n/a | 960 | Luc Mongeau | www.canopygrowth.com |
キャノピー・グロース・コーポレーションは、その子会社とともに、主に米国、カナダ、ドイツ、および国際的なレクリエーションおよび医療目的の大麻およびヘンプベースの製品の生産、流通、販売に従事している。カナダ・カンナビス（Canada Cannabis）、インターナショナル・マーケット・カンナビス（International Markets Cannabis）、シュトルツ＆ビッケル（Storz & Bickel）の各セグメントを通じて事業を展開している。同社は、ドライフラワー、プレロールジョイント、オイル、ソフトジェルカプセル、インフューズド飲料、グミからなるエディブル、局所用フォーマット、およびヴェポライザーデバイスを提供している。同社はTweed、7ACRES、DOJA、Deep Space、HiWay、Maitri、Twd.、Vert、Spectrum Therapeutics、Canopy Medical、Storz & Bickel、Martha Stewart、Wanaのブランドで製品を販売している。同社は以前Tweed Marijuana Inc.として知られていたが、2015年9月にキャノピー・グロース・コーポレーションに社名を変更した。キャノピー・グロース・コーポレーションは2009年に法人化され、カナダのスミスフォールズに本社を置いている。
Canopy Growth Corporation 基礎のまとめ
| WEED 基礎統計学 | |
|---|---|
| 時価総額 | CA$556.00m |
| 収益（TTM） | -CA$327.29m |
| 売上高(TTM) | CA$278.39m |
2.1x
P/Sレシオ-1.8x
PER（株価収益率WEED は割高か？
公正価値と評価分析を参照収益と収入
| WEED 損益計算書（TTM） | |
|---|---|
| 収益 | CA$278.39m |
| 売上原価 | CA$204.45m |
| 売上総利益 | CA$73.94m |
| その他の費用 | CA$401.24m |
| 収益 | -CA$327.29m |
直近の収益報告
Dec 31, 2025
次回決算日
Jun 15, 2026
| 一株当たり利益（EPS） | -0.86 |
| グロス・マージン | 26.56% |
| 純利益率 | -117.57% |
| 有利子負債／自己資本比率 | 29.7% |
WEED の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/25 14:28 |
| 終値 | 2026/05/25 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/03/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Canopy Growth Corporation 5 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。23
| アナリスト | 機関 |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Jesse Pytlak | ATB Cormark Historical (Cormark Securities) |